Bionomics (BNOX) Competitors $0.25 +0.01 (+4.20%) (As of 12/23/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BNOX vs. CTXR, TENX, CGTX, FNCH, CARM, MIRA, UBX, CVKD, PIRS, and SYBXShould you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include Citius Pharmaceuticals (CTXR), Tenax Therapeutics (TENX), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Carisma Therapeutics (CARM), MIRA Pharmaceuticals (MIRA), Unity Biotechnology (UBX), Cadrenal Therapeutics (CVKD), Pieris Pharmaceuticals (PIRS), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. Bionomics vs. Citius Pharmaceuticals Tenax Therapeutics Cognition Therapeutics Finch Therapeutics Group Carisma Therapeutics MIRA Pharmaceuticals Unity Biotechnology Cadrenal Therapeutics Pieris Pharmaceuticals Synlogic Citius Pharmaceuticals (NASDAQ:CTXR) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations. Is CTXR or BNOX more profitable? Bionomics' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -44.65% -39.39% Bionomics N/A N/A N/A Does the MarketBeat Community believe in CTXR or BNOX? Citius Pharmaceuticals received 189 more outperform votes than Bionomics when rated by MarketBeat users. However, 76.92% of users gave Bionomics an outperform vote while only 62.20% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCitius PharmaceuticalsOutperform Votes20962.20% Underperform Votes12737.80% BionomicsOutperform Votes2076.92% Underperform Votes623.08% Which has more risk & volatility, CTXR or BNOX? Citius Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Bionomics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Which has stronger valuation & earnings, CTXR or BNOX? Bionomics has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$32.54M-$6.00-0.52Bionomics$10K446.82-$15.49MN/AN/A Does the media favor CTXR or BNOX? In the previous week, Bionomics had 4 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 5 mentions for Bionomics and 1 mentions for Citius Pharmaceuticals. Bionomics' average media sentiment score of 0.57 beat Citius Pharmaceuticals' score of 0.00 indicating that Bionomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bionomics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of CTXR or BNOX? 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Bionomics shares are owned by institutional investors. 15.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Bionomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend CTXR or BNOX? Citius Pharmaceuticals currently has a consensus target price of $100.00, suggesting a potential upside of 3,094.89%. Bionomics has a consensus target price of $8.00, suggesting a potential upside of 3,060.81%. Given Citius Pharmaceuticals' higher probable upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Bionomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Bionomics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBionomics beats Citius Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Bionomics News Delivered to You Automatically Sign up to receive the latest news and ratings for BNOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNOX vs. The Competition Export to ExcelMetricBionomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.47M$6.71B$5.22B$9.27BDividend YieldN/A3.00%5.12%4.30%P/E RatioN/A10.5487.3417.27Price / Sales446.82195.831,166.41119.61Price / CashN/A57.1443.2337.83Price / Book0.195.164.834.93Net Income-$15.49M$151.58M$120.46M$225.34M7 Day Performance-3.40%4.12%2.84%4.14%1 Month Performance-10.02%-3.99%19.70%1.16%1 Year Performance-80.68%10.33%30.57%16.98% Bionomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNOXBionomics2.7685 of 5 stars$0.25+4.2%$8.00+3,060.8%-80.7%$4.47M$10,000.000.00N/AGap UpHigh Trading VolumeCTXRCitius Pharmaceuticals1.72 of 5 stars$2.75-1.4%$100.00+3,536.4%-84.3%$19.88MN/A-0.4720News CoverageTENXTenax Therapeutics1.4985 of 5 stars$5.80-1.4%$16.00+175.9%-77.1%$19.78MN/A0.009Gap UpCGTXCognition Therapeutics2.9633 of 5 stars$0.46-3.1%$8.00+1,627.9%-61.9%$19.24MN/A-0.4920FNCHFinch Therapeutics GroupN/A$11.75-2.1%N/A+203.4%$18.87M$110,000.00-1.36190CARMCarisma Therapeutics3.3865 of 5 stars$0.45+11.4%$4.94+995.1%-87.2%$18.83M$20.27M-0.2620Gap DownHigh Trading VolumeMIRAMIRA Pharmaceuticals2.4532 of 5 stars$1.12flat$14.00+1,150.0%+0.9%$18.55MN/A-2.002Analyst RevisionUBXUnity Biotechnology3.1506 of 5 stars$1.10-1.8%$8.00+627.3%-37.5%$18.54M$240,000.00-0.8460CVKDCadrenal Therapeutics1.7675 of 5 stars$11.06-1.3%$18.00+62.7%N/A$18.35MN/A-1.684PIRSPieris Pharmaceuticals1.3297 of 5 stars$13.60-15.7%N/A+7.9%$17.95M$42.81M-1.12140Gap DownSYBXSynlogicN/A$1.50flatN/A-61.8%$17.55M$3.37M-0.366 Related Companies and Tools Related Companies CTXR Competitors TENX Competitors CGTX Competitors FNCH Competitors CARM Competitors MIRA Competitors UBX Competitors CVKD Competitors PIRS Competitors SYBX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BNOX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.